Flutamide


Concise Prescribing Info
Indications/Uses
Palliation of prostatic carcinoma.
Dosage/Direction for Use
Adult : PO 250 mg 3 times/day.
Dosage Details
Oral
Palliative treatment of prostatic carcinoma
Adult: 250 mg tid preferably at least 3 days before gonadorelin analogue treatment.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity, severe hepatic impairment, pregnancy and lactation.
Special Precautions
Perform liver function tests before starting treatment and at regular intervals. Treatment is not recommended in patients whose ALT values exceed twice the upper limit of normal. Regular assessment of prostate specific antigen level may help to monitor disease progression. Advise patient against discontinuing drug on their own. Exercise caution in patients with cardiac disease.
Adverse Reactions
Hot flushes, loss of libido, impotence, gynaecomastia, nausea, vomiting, diarrhoea, increased appetite, sleep disturbances, skin reactions, anaemias, headache, dizziness, malaise, anxiety, hypertension, gastric and chest pain, oedema, blurred vision, hepatitis, jaundice, rash, thirst, pruritus, SLE-like syndrome, drowsiness, confusion, depression, nervousness.
Drug Interactions
Increased prothrombin time in patients on long-term warfarin treatment.
Action
Description: Flutamide is a nonsteroidal 'pure' antiandrogen which acts directly on the target tissues either by blocking androgen uptake or by inhibiting cytoplasmic and nuclear binding of androgen.
Pharmacokinetics:
Distribution: Protein-binding: 90%
Metabolism: Rapid and extensive; converted to hydroxyflutamide.
Excretion: Urine, faeces (small amounts); 2 hrs (elimination half-life, metabolite).
Storage
Store at 25°C.
Disclaimer: This information is independently developed by MIMS based on Flutamide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Fugerel
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in